ShakeelModakMD

Pediatric Hematology & Oncology • New York, NY

Physician

Overview of Dr. Modak

Dr. Shakeel Modak is a pediatric hematologist/oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, New York-Presbyterian Hospital, New York-Presbyterian Hospital, and New York-Presbyterian Hospital. He received his medical degree from Topiwala National Medical College and has been in practice 29 years. He is one of 95 doctors at Memorial Sloan Kettering Cancer Center and one of 135 doctors at New York-Presbyterian Hospital who specialize in Pediatric Hematology & Oncology. He has more than 100 publications and over 500 citings.

Office
1275 York Avenue
New York, NY 10065
Book by Phone+1(805) 419-2431

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1996 - 1999
Central Iowa Health System (Iowa Methodist Medical Center)Residency, Pediatrics, 1995 - 1996
Topiwala National Medical CollegeClass of 1988

Certifications & Licensure

NY State Medical License 2001 - 2025
IA State Medical License 1995 - 1996
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

New York Magazine: Top Doctors Castle Connolly, 2014-2020

Clinical Trials

Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation Start of enrollment: 2004 May 01
Terminated
Phase 1
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma Start of enrollment: 2006 May 01
Recruiting
Phase 2
Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma Start of enrollment: 2006 Aug 01
Completed
Phase 1
Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma Start of enrollment: 2005 Sep 09
Completed
Phase 1
Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9 Start of enrollment: 2001 Oct 01
Terminated
Not Applicable
Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma Start of enrollment: 2009 Apr 02
Completed
Phase 1
Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum Start of enrollment: 2010 Apr 01
Terminated
Phase 1
Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma Start of enrollment: 2010 Apr 29
Completed
Phase 2
Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) Start of enrollment: 2013 Aug 28
Completed
Phase 1
Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma Start of enrollment: 2016 Jan 01
Active, not recruiting
Phase 1
Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers Start of enrollment: 2019 Feb 22
Terminated
Phase 1, Phase 2
A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum Start of enrollment: 2019 Jul 15
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

3 citations
Local anesthesia with general anesthesia for pediatric bone marrow procedures
Sara Zarnegar-Lumley, Katharine R. Lange, Melissa Mathias, Miho Nakajima-Hatano, Katharine M. Offer
Pediatrics. 2019-08-01
187 citations
Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neur...
Nai-Kong V. Cheung, Irene Y. Cheung, Brian H. Kushner, Irina Ostrovnaya, Elizabeth Chamberlain
Journal of Clinical Oncology. 2012-09-10
87 citations
Phase I Trial of a Bivalent Gangliosides Vaccine in Combination with β-Glucan for High-Risk Neuroblastoma in Second or Later Remission
Brian H. Kushner, Irene Y. Cheung, Shakeel Modak, Kim Kramer, Govind Ragupathi
Clinical Cancer Research. 2014-03-01

Press Mentions

Y-mAbs Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuroblastoma Meets Primary EndpointMay 26th, 2022
Y-mAbs to Host Key Opinion Leader Webinar on DANYELZA® (Naxitamab-Gqgk) Frontline and HITS Data in High-Risk NeuroblastomaSeptember 10th, 2021
Y-mAbs to Host Virtual Research & Development Day on Wednesday, December 16December 7th, 2020
Join now to see all